IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS
Hepatic Impairment
Elevated Liver Enzymes
Gastrointestinal Disorders
Diarrhea
Nausea and Vomiting

Embryofetal Toxicity: OFEV can cause fetal harm when administered to a pregnant woman and patients should be advised of the potential risk to a fetus. Women should be advised to avoid becoming pregnant while receiving OFEV and to use effective contraception during treatment and at least 3 months after the last dose of OFEV. Verify pregnancy status prior to starting OFEV.

Arterial Thromboembolic Events: Arterial thromboembolic events were reported in 2.5% of OFEV and 0.8% of placebo patients, respectively. Myocardial infarction was the most common arterial thromboembolic event, occurring in 1.5% of OFEV and 0.4% of placebo patients. Use caution when treating patients at higher cardiovascular risk including known coronary artery disease. Consider treatment interruption in patients who develop signs or symptoms of acute myocardial ischemia.

Risk of Bleeding: OFEV may increase the risk of bleeding. Bleeding events were reported in 10% of OFEV versus 7% of placebo patients. Use OFEV in patients with known risk of bleeding only if the anticipated benefit outweighs the potential risk.

Gastrointestinal Perforation: OFEV may increase the risk of gastrointestinal perforation. Gastrointestinal perforation was reported in 0.3% of OFEV versus in 0% placebo patients. Use caution when treating patients who have had recent abdominal surgery. Discontinue therapy with OFEV in patients who develop gastrointestinal perforation. Only use OFEV in patients with known risk of gastrointestinal perforation if the anticipated benefit outweighs the potential risk.

ADVERSE REACTIONS
DRUG INTERACTIONS
USE IN SPECIFIC POPULATIONS

Please see accompanying full Prescribing Information, including Patient Information.

INDICATION AND USAGE

OFEV is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

Reference

  1. OFEV® (nintedanib) Prescribing Information. Ridgefield, CT: Boehringer lngelheim Pharmaceuticals. Inc; 2014.

Copyright ©2016 Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved.
3/16 PC-OF-0400-PROF